164 related articles for article (PubMed ID: 34858809)
41. Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who received second-line immune checkpoint inhibitors.
Miron B; Handorf E; Zarrabi K; Zibelman MR; Anari F; Ghatalia P; Plimack ER; Geynisman DM
Urol Oncol; 2022 Oct; 40(10):454.e9-454.e16. PubMed ID: 35788287
[TBL] [Abstract][Full Text] [Related]
42. A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer.
Peirce V; Paskow M; Qin L; Dadzie R; Rapoport M; Prince S; Johal S
Target Oncol; 2023 Nov; 18(6):837-852. PubMed ID: 37751011
[TBL] [Abstract][Full Text] [Related]
43. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
[TBL] [Abstract][Full Text] [Related]
44. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial.
Lamarca A; Palmer DH; Wasan HS; Ross PJ; Ma YT; Arora A; Falk S; Gillmore R; Wadsley J; Patel K; Anthoney A; Maraveyas A; Iveson T; Waters JS; Hobbs C; Barber S; Ryder WD; Ramage J; Davies LM; Bridgewater JA; Valle JW;
Lancet Oncol; 2021 May; 22(5):690-701. PubMed ID: 33798493
[TBL] [Abstract][Full Text] [Related]
45. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
Front Immunol; 2022; 13():946861. PubMed ID: 35967452
[TBL] [Abstract][Full Text] [Related]
46. Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice.
Grivas P; Grande E; Davis ID; Moon HH; Grimm MO; Gupta S; Barthélémy P; Thibault C; Guenther S; Hanson S; Sternberg CN
ESMO Open; 2023 Dec; 8(6):102050. PubMed ID: 37976999
[TBL] [Abstract][Full Text] [Related]
47. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
Galsky MD; Pal SK; Lin SW; Ogale S; Zivkovic M; Simpson J; Derleth C; Schiff C; Sonpavde G
Bladder Cancer; 2018 Apr; 4(2):227-238. PubMed ID: 29732393
[TBL] [Abstract][Full Text] [Related]
48. Modified FOLFIRINOX versus gemcitabine plus oxaliplatin as first-line chemotherapy for patients with locally advanced or metastatic cholangiocarcinoma: a retrospective comparative study.
Zou L; Li X; Wu X; Cui J; Cui X; Song X; Ren T; Han X; Zhu Y; Li H; Wu W; Wang X; Gong W; Wang L; Li M; Lau WY; Liu Y
BMC Cancer; 2021 Jul; 21(1):818. PubMed ID: 34266407
[TBL] [Abstract][Full Text] [Related]
49. Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
Aguin S; Carral A; Iglesias L; Pena C; Molina A; Costa M; Covela M; Gomez JG; Arroyo RG; Huidobro G; Simo RV; Medina A
Cancer Diagn Progn; 2023; 3(2):264-271. PubMed ID: 36875311
[TBL] [Abstract][Full Text] [Related]
50. High platelet-to-lymphocyte ratio is associated with poor prognosis in patients with unresectable intrahepatic cholangiocarcinoma receiving gemcitabine plus cisplatin.
Huh G; Ryu JK; Chun JW; Kim JS; Park N; Cho IR; Paik WH; Lee SH; Kim YT
BMC Cancer; 2020 Sep; 20(1):907. PubMed ID: 32967632
[TBL] [Abstract][Full Text] [Related]
51. Phase II Trial of Combination Nab-paclitaxel and Gemcitabine in Non-squamous Non-small Cell Lung Cancer After Progression on Platinum and Pemetrexed.
Ciunci CA; Reibel JB; Evans TL; Mick R; Bauml JM; Aggarwal C; Marmarelis ME; Singh AP; D'Avella C; Cohen RB; Langer CJ
Clin Lung Cancer; 2022 Jun; 23(4):e310-e316. PubMed ID: 35393247
[TBL] [Abstract][Full Text] [Related]
52. Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
Williams CD; Allo MA; Gu L; Vashistha V; Press A; Kelley M
PLoS One; 2023; 18(2):e0282020. PubMed ID: 36809528
[TBL] [Abstract][Full Text] [Related]
53. Long term responders to palliative chemotherapy for advanced biliary tract cancer.
Doherty MK; McNamara MG; Aneja P; McInerney E; Moignard S; Horgan AM; Jiang H; Panzarella T; Jang R; Dhani N; Hedley D; Knox JJ
J Gastrointest Oncol; 2017 Apr; 8(2):352-360. PubMed ID: 28480074
[TBL] [Abstract][Full Text] [Related]
54. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.
Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
Urol Oncol; 2017 Sep; 35(9):542.e1-542.e9. PubMed ID: 28619633
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of first-line chemotherapy in patients with advanced lung sarcomatoid carcinoma.
Vieira T; Girard N; Ung M; Monnet I; Cazes A; Bonnette P; Duruisseaux M; Mazieres J; Antoine M; Cadranel J; Wislez M
J Thorac Oncol; 2013 Dec; 8(12):1574-7. PubMed ID: 24389441
[TBL] [Abstract][Full Text] [Related]
56. Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis.
Lee JL; Desai C; Park SH; Tsuchiya N; Su PJ; Chan TTW; Gurney H; Gao S; Wang J; Sandner R; di Pietro A; Eto M
Urol Oncol; 2023 May; 41(5):256.e17-256.e25. PubMed ID: 37019764
[TBL] [Abstract][Full Text] [Related]
57. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
[TBL] [Abstract][Full Text] [Related]
58. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada.
Beaulieu C; Lui A; Yusuf D; Abdelaziz Z; Randolph B; Batuyong E; Ghosh S; Bathe OF; Tam V; Spratlin JL
Curr Oncol; 2021 Jan; 28(1):417-427. PubMed ID: 33450805
[No Abstract] [Full Text] [Related]
59. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
[TBL] [Abstract][Full Text] [Related]
60. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]